As of 2025-05-03, the EV/EBITDA ratio of Aprea Therapeutics Inc (APRE) is 0.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. APRE's latest enterprise value is -12.62 mil USD. APRE's TTM EBITDA according to its financial statements is -14.30 mil USD. Dividing these 2 quantities gives us the above APRE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 12.0x | 10.6x |
| Forward P/E multiples | 15.7x - 32.7x | 19.9x |
| Fair Price | (36.46) - (26.89) | (35.30) |
| Upside | -2070.9% - -1553.7% | -2008.0% |
| Date | EV/EBITDA |
| 2025-05-01 | 0.90 |
| 2025-04-30 | 0.93 |
| 2025-04-29 | 0.94 |
| 2025-04-28 | 0.92 |
| 2025-04-25 | 0.98 |
| 2025-04-24 | 0.97 |
| 2025-04-23 | 1.02 |
| 2025-04-22 | 1.00 |
| 2025-04-21 | 1.03 |
| 2025-04-17 | 1.02 |
| 2025-04-16 | 1.00 |
| 2025-04-15 | 0.99 |
| 2025-04-14 | 0.99 |
| 2025-04-11 | 1.00 |
| 2025-04-10 | 1.00 |
| 2025-04-09 | 0.99 |
| 2025-04-08 | 0.96 |
| 2025-04-07 | 0.98 |
| 2025-04-04 | 0.94 |
| 2025-04-03 | 0.90 |
| 2025-04-02 | 0.87 |
| 2025-04-01 | 0.86 |
| 2025-03-31 | 0.81 |
| 2025-03-28 | 0.79 |
| 2025-03-27 | 0.75 |
| 2025-03-26 | 0.73 |
| 2025-03-25 | 0.75 |
| 2025-03-24 | 0.72 |
| 2025-03-21 | 0.67 |
| 2025-03-20 | 0.66 |
| 2025-03-19 | 0.69 |
| 2025-03-18 | 0.68 |
| 2025-03-17 | 0.69 |
| 2025-03-14 | 0.67 |
| 2025-03-13 | 0.68 |
| 2025-03-12 | 0.66 |
| 2025-03-11 | 0.65 |
| 2025-03-10 | 0.74 |
| 2025-03-07 | 0.70 |
| 2025-03-06 | 0.64 |
| 2025-03-05 | 0.58 |
| 2025-03-04 | 0.61 |
| 2025-03-03 | 0.70 |
| 2025-02-28 | 0.62 |
| 2025-02-27 | 0.63 |
| 2025-02-26 | 0.61 |
| 2025-02-25 | 0.62 |
| 2025-02-24 | 0.61 |
| 2025-02-21 | 0.58 |
| 2025-02-20 | 0.50 |